10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
REGENERON PHARMACEUTICALS, INC. | ||
Ticker: REGN Fiscal Year: 2017 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2017 10-K (Filed: Feb 8, 2018) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2017 | Dec 31, 2016 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $ 812,733 | 535,203 |
| Marketable securities | 596,847 | 503,481 |
| Accounts receivable - trade, net | 1,538,642 | 1,343,368 |
| Accounts receivable from Sanofi | 193,684 | 92,989 |
| Accounts receivable from Bayer | 242,014 | 175,263 |
| Inventories | 726,138 | 399,356 |
| Prepaid expenses and other current assets | 224,972 | 130,528 |
| Total current assets | 4,335,030 | 3,180,188 |
| Marketable securities | 1,486,494 | 864,260 |
| Property, plant, and equipment, net | 2,358,605 | 2,083,421 |
| Deferred tax assets | 506,291 | 825,303 |
| Other assets | 77,866 | 20,294 |
| Total assets | 8,764,286 | 6,973,466 |
| LIABILITIES and STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | 815,078 | 879,096 |
| Capital and facility lease obligations | 0 | 129,557 |
| Deferred revenue from Sanofi, current portion | 177,746 | 115,267 |
| Deferred revenue - other, current portion | 142,392 | 116,397 |
| Other current liabilities | 267 | 1,178 |
| Total current liabilities | 1,135,483 | 1,241,495 |
| Capital and facility lease obligations, noncurrent | 703,453 | 351,569 |
| Deferred revenue from Sanofi | 379,936 | 503,474 |
| Deferred revenue - other | 249,263 | 327,298 |
| Other long term liabilities | 152,073 | 100,385 |
| Total liabilities | 2,620,208 | 2,524,221 |
| Commitments and contingencies (Note 12) | ||
| Stockholders' equity: | ||
| Preferred Stock | 0 | 0 |
| Additional paid-in capital | 3,512,833 | 3,029,993 |
| Retained earnings | 2,946,733 | 1,748,222 |
| Accumulated other comprehensive (loss) income | 640 | (12,840) |
| Treasury Stock | (316,240) | (316,240) |
| Total stockholders' equity | 6,144,078 | 4,449,245 |
| Total liabilities and stockholders' equity | 8,764,286 | 6,973,466 |
| Class of Stock | ||
| Class A Stock | ||
| Common stock | 2 | 2 |
| Total stockholders' equity | 2 | 2 |
| Common Stock | ||
| Common stock | 110 | 108 |
| Total stockholders' equity | 110 | 108 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2017 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |